Shree Ganesh Biotech (India) share price
BSE: 539470Pharmaceuticals & BiotechnologySmall Cap
Last close ₹0.44₹0.00 (0.00%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹0.44.
52-week range of traded prices to 23 Oct 2026
₹0.44Low, 12 Oct 2026₹0.78High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹18 Cr3,998th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 0.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- −2.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,26,279
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 4 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1.43 Crdown 32.59%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.57 CrQuarter to Mar 2026: −₹0.15 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −40.1%
Revenue by year
Peak revenue ₹73 Cr, year to Mar 2022
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 4 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 25 Jul | Sep 2025Filed 8 Nov | Dec 2025Filed 29 Jan | Mar 2026Filed 14 May | Jun 2026Filed 4 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0 | 14.4 | 3.0 | 1.4 | 0.8 | 0.7 | 2.1 | 1.4 |
| Net profit | 0.3 | 0.8 | −0.9 | 0.3 | 0.0 | 0.3 | −0.1 | −0.6 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 16.3% | 5.4% | −31.5% | 23.6% | 1.8% | 46.2% | −7.0% | −40.1% |
Standalone. The last eight quarters. The latest is shaded.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 0.2% of 1,239 trading days over the last 5 years.
LowestHighest
Its median0.7Industry median2.9
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −40.0% | +35.7% | −55.8% | 0.0% |
| 3 years | −19.1% | −43.0% | +41.9% | 0.0% |
| 5 years | −38.1% | +3.6% | −40.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Peers and competitors
Pharmaceuticals & Biotechnology, 222 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Shree Ganesh Biotech (India) in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Shree Ganesh Biotech (India) is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Walpar NutritionsWALPAR | 25 | 9.9 | 1.3 | – | +9.8% | −42.7% | 14.0% | – | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 22 | – | – | – | – | – | – | – | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 21 | 29.6 | 1.8 | 24.8 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
 Centuple GlobalCENTUPLE | 20 | 16.4 | 9.8 | 13.4 | +4,540.6% | +1,281.3% | 94.1% | 22.8% | 0.00% |
 Zenith Health CareZENITHHE | 17 | 107.1 | 2.3 | 97.9 | −9.3% | – | 2.2% | −1.2% | 0.00% |
 Colinz LaboratoriesCOLINZ | 17 | 6.1 | 1.7 | 26.5 | −8.4% | +484.3% | 28.7% | 1.7% | 0.00% |
 Span DivergentSDL | 17 | – | 1.1 | – | +171.7% | – | – | −24.0% | 0.00% |
 Venmax Drugs and PharmaceuticalsVENMAX | 17 | – | – | – | +385.7% | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Shree Ganesh Biotech (India) share price by year
Each calendar year to 2025.Shree Ganesh Biotech (India) share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 0.62 | −40.4% | 1.12 | 0.60 |
| 2024 | 1.04 | −42.2% | 1.71 | 1.00 |
| 2023 | 1.80 | +20.8% | 1.89 | 0.73 |
| 2022 | 1.49 | −79.0% | 7.29 | 1.31 |
| 2021 | 7.09 | +25.1% | 9.64 | 5.70 |
| 2020 | 5.67 | −8.6% | 6.75 | 4.60 |
| 2019 | 6.20 | −2.4% | 6.80 | 5.70 |
| 2018 | 6.35 | −41.8% | 23.99 | 6.35 |
| 2017 | 10.92 | – | 14.41 | 4.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 16 Jan 2020. 2017 is from its first session, 22 Sep 2017.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 0.45 | 0.45 | 0.44 | 0.44 | 0.44 | 2,26,279 |
| 22 Oct 2026 | 0.45 | 0.46 | 0.44 | 0.44 | 0.45 | 2,15,493 |
| 21 Oct 2026 | 0.47 | 0.47 | 0.45 | 0.46 | 0.45 | 2,38,078 |
| 19 Oct 2026 | 0.46 | 0.47 | 0.45 | 0.45 | 0.46 | 5,13,527 |
| 16 Oct 2026 | 0.46 | 0.47 | 0.46 | 0.46 | 0.46 | 4,49,982 |
| 15 Oct 2026 | 0.46 | 0.47 | 0.46 | 0.47 | 0.47 | 4,05,806 |
| 14 Oct 2026 | 0.47 | 0.47 | 0.46 | 0.47 | 0.46 | 1,72,700 |
| 13 Oct 2026 | 0.46 | 0.47 | 0.46 | 0.47 | 0.47 | 5,51,685 |
| 12 Oct 2026 | 0.47 | 0.47 | 0.44 | 0.47 | 0.46 | 8,95,557 |
| 9 Oct 2026 | 0.46 | 0.47 | 0.46 | 0.47 | 0.46 | 2,84,536 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 27 Apr 2022 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 10 Feb 2022 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Shree Ganesh Biotech (India) Limited
- BSE code
- 539470
- ISIN
- INE051N01026
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Nov 2015
- Face value
- ₹1
- CIN
- L70101WB1982PLC121196
- Corporate identity number, the registrar of companies' code for it